What is William Blair’s Forecast for TARS FY2026 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at William Blair dropped their FY2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research report issued on Monday, July 14th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of $1.67 for the year, down from their prior estimate of $1.94. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share.

Several other brokerages have also recently weighed in on TARS. Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an “outperform” rating and a $75.00 price target on the stock. The Goldman Sachs Group raised their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a “neutral” rating in a report on Monday, May 5th. HC Wainwright upgraded Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 price objective on the stock in a report on Tuesday, May 27th. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, Guggenheim lifted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $40.58 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.57 and a quick ratio of 5.54. The business has a 50 day simple moving average of $42.12 and a 200-day simple moving average of $46.83. The firm has a market capitalization of $1.70 billion, a PE ratio of -14.86 and a beta of 0.80. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. The firm had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP boosted its stake in shares of Tarsus Pharmaceuticals by 3.1% in the first quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company’s stock valued at $134,086,000 after purchasing an additional 78,301 shares during the period. Vanguard Group Inc. lifted its holdings in Tarsus Pharmaceuticals by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock worth $114,380,000 after buying an additional 111,433 shares in the last quarter. Toronto Dominion Bank purchased a new position in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $105,714,000. Lord Abbett & CO. LLC grew its stake in shares of Tarsus Pharmaceuticals by 4.0% in the first quarter. Lord Abbett & CO. LLC now owns 1,331,701 shares of the company’s stock worth $68,409,000 after acquiring an additional 51,714 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Tarsus Pharmaceuticals by 36.7% in the fourth quarter. Invesco Ltd. now owns 932,115 shares of the company’s stock worth $51,611,000 after acquiring an additional 250,018 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.